title: Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases.
abstract: Insulin resistance syndrome (IRS) is associated with increased cardiovascular morbidity and mortality. IRS is becoming one of the major health problems as its prevalence grows rapidly. Accelerated atherothrombotic process in the IRS is attributed to metabolic abnormalities, inflammation and to impaired fibrinolysis due to increased plasma plasminogen activator inhibitor type 1 (PAI-1) levels. Proinflammatory cytokines may have an important role in PAI-1 overexpression, particularly in the adipose tissue. Studies in genetically modified mice indicate that PAI-1 might be involved in the aetiopathogenesis of obesity. Modifying PAI-1 expression by PAI-1 inhibitors may open a new field of research and may reveal the true role of PAI-1 in atherosclerotic and insulin resistance processes.
authors.affiliation: Laboratory of Hematology, CHU Timone, Marseille, France.
authors.forename: A
authors.initials: A
authors.lastname: Mavri
authors.forename: M-C
authors.initials: MC
authors.lastname: Alessi
authors.forename: I
authors.initials: I
authors.lastname: Juhan-Vague
mesh_terms: D000273:Adipose Tissue / Q000503:physiopathology; D000818:Animals; D001161:Arteriosclerosis / Q000503:physiopathology; D002318:Cardiovascular Diseases / Q000209:etiology / Q000503:physiopathology*; D005342:Fibrinolysis / Q000502:physiology*; D006801:Humans; D007249:Inflammation / Q000503:physiopathology; D024821:Metabolic Syndrome / Q000150:complications / Q000503:physiopathology*; D051379:Mice; D009765:Obesity / Q000209:etiology / Q000503:physiopathology; D017395:Plasminogen Activator Inhibitor 1 / Q000502:physiology
chemical_list: D017395:Plasminogen Activator Inhibitor 1